Convalescent (Immune) Plasma Therapy in the Treatment of Critical Patients Infected with SARS-Cov-2 Virus

Year 2020, COVID-19Special Issue, 128 - 134, 30.04.2020

Tuba Hacıbekiroğlu Tuğçe Nur Yiğenoğlu Yasin Kalpakcı

https://doi.org/10.34084/bshr.722553

Cited By: 1

Abstract

SARS-CoV-2 Virüsü ile Enfekte Kritik Düzey Hastaların Tedavisinde Konvelesan (İmmun) Plazma Kullanımı

Abstract

Çin Halk Cumhuriyeti’nin Wuhan Eyaletinde yarasadan insana bulaş yolu ile tesbit edilen coronavirüs ailesinden Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virüsü çok hızlı bir yayılım göstererek çok kısa bir sürede tüm dünyada etkisini göstermiştir. 11 Şubat 2020 tarihinde bu virüsün yol açtığı hastalığı COVİD-19 olarak adlandıran Dünya Sağlık Örgütü (WHO) 11 Mart 2020 tarihinde bu salgın hastalığı pandemi olarak ilan etmiştir. Konvelesan plazma (KP) tedavisi tarihteki salgın hastalık dönemlerinde kullanılmış, etkili olduğu gösterilmiş bir pasif antikor tedavisidir. Konvelesan plazmanın etki mekanizmaları arasında virüsü direkt bağlayarak nötrolize etmek, kompleman aktivasyonu, antikor bağımlı sellüler sitotoksisite ve/veya fagositoz yollarıyla virüs eliminasyonunu başlatmak sayılabilir. Nötralizan antikorlar bu etki mekanizmalarında çok önemlidir. Virüsü inaktive ederek viral replikasyonu engellemesi iyileşmedeki en önemli noktadır. Bu yüzden KP da nötrolizan antikor titresi ölçümü önemlidir. Nötralizan olmayan antikorların viral replikasyonu durdurmadığı in vitro olarak gösterilmiş ve bu antikorların proflakside kullanılabileceği, iyileşmede destekleyici etkileri olduğu öne sürülmüştür. COVİD-19 hastalığında yapılan çalışmalarda da KP nın etkili olduğu görülmüştür. Ülkemizde ve Amerikada yakın zamanda tedavi endikasyonu alan bu tedavi yönteminin uygulama kriterleri her iki ülke tarafından belirlenmiştir. Uygun donorlerden, fayda görebilecek hastalara nakledilen konvelesan plazma tedavi sonuçları merakla beklenmektedir.

Keywords

Konvelesan Plazma

References

• 1- JHU. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering at Johns Hopkins. https://coronavirus.jhu.edu/map.html. Updated April 4, 2020 Accessed April 5, 2020.
• 2- WHO. Rolling updates on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Updated March 17, 2020 Accessed March 18, 2020.
• 3- Casadevall A, and Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150-61.
• 4- Stokes J, Jr., Wolman Ij, Carpenter Hc, And Margolıs J. Prophylactıc Use Of Parents' Whole Blood In Anterıor Polıomyelıtıs: Phıladelphıa Epıdemıc Of 1932. American Journal Of Diseases Of Children. 1935;50(3):581-95.
• 5- Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-56.
• 6- Zhou B, Zhong N, and Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1.
• 7- Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77(2):147-50.
• 8- Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-22.
• 9- van Erp EA, Luytjes W, Ferwerda G, and van Kasteren PB. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. Front Immunol. 2019;10:548.
• 10- Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host Microbe. 2018;24(2):221-33.e5
• 11- Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.
• 12- Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-22.
• 13- Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919-22
• 14- Xinhua. China puts 245 COVID-19 patients on convalescent plasma therapy http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm. Accessed March 18, 2020.
• 15- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.
• 16- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020:2020.03.16.20036145. 23
• 17- CBER. Investigational COVID-19 Convalescent Plasma Emergency INDs. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds. Accessed March 24, 2020.
• 18- Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. 2020:2020.03.17.20037713.
• 19- Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol. 2020.
• 20- OKBA NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020:2020.03.18.20038059.
• 21- file:///D:/covid/37151,covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberipdf.pdf
• 22- Dennis McGonaglea,b,⁎, Kassem Sharifa,c, Anthony O'Regand, Charlie Bridgewooda The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
• 23- Hendrickson JE, and Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759-69.
• 24- AABB. Standards for Blood Banks and Transfusion Services. Bethesda, MD: AABB; 2018.
• 25- Chang L, Zhao L, Gong H, Wang L, and Wang L. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations. Emerg Infect Dis. 2020;26(7).
• 26- FDA. Electronic Code of Federal Regulations: 630.30 Donation suitability requirements. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3. Updated March 17, 2020 Accessed March 19, 2020.
• 27- Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020.